The impact of anti-U1-RNP positivity: systemic lupus erythematosus versus mixed connective tissue disease
Tóm tắt
Từ khóa
Tài liệu tham khảo
Cervera R, Khamashta M, Hughes G (2009) The Euro-lupus project: epidemiology of systemic lupus erythematosus in Europe. Lupus 18(10):869–874. https://doi.org/10.1177/0961203309106831
To CH, Petri M (2005) Is antibody clustering predictive of clinical subsets and damage in systemic lupus erythematosus? Arthritis Rheum 52:4003–4010. https://doi.org/10.1002/art.21414
Bertoli AM, Vila LM, Apte M et al (2007) Systemic lupus erythematosus in a multiethnic US Cohort LUMINA XLVIII: factors predictive of pulmonary damage. Lupus 16:410–417. https://doi.org/10.1177/0961203307079042
Boddaert J, Huong DLT, Amoura Z et al (2004) Late-onset systemic lupus erythematosus: a personal series of 47 patients and pooled analysis of 714 cases in the literature. Medicine (Baltimore) 83:348–359
Mattioli M, Reichlin M (1971) Characterization of a soluble nuclear ribonucleoprotein antigen reactive with SLE sera. J Immunol 107:1281–1290
Benito-Garcia E, Schur PH, Lahita R et al (2004) Guidelines for immunologic laboratory testing in the rheumatic diseases: anti-Sm and anti-RNP antibody tests. Arthritis Rheum 51:1030–1044. https://doi.org/10.1002/art.20836
Tan EM, Kunkel HG (1966) Characteristics of a soluble nuclear antigen precipitating with sera of patients with systemic lupus erythematosus. J Immunol 96:464–471
Poole BD, Schneider RI, Guthridge JM et al (2009) Early targets of nuclear RNP humoral autoimmunity in human systemic lupus erythematosus. Arthritis Rheum 60:848–859. https://doi.org/10.1002/art.24306
Amigues JM, Cantagrel A, Abbal M et al (1996) Comparative study of 4 diagnosis criteria sets for mixed connective tissue disease in patients with anti-RNP antibodies. Autoimmunity Group of the Hospitals of Toulouse. J Rheumatol 23:2055–2062
Cappelli S, Bellando RS, Martinović D et al (2012) “To be or not to be,” ten years after: evidence for mixed connective tissue disease as a distinct entity. Semin Arthritis Rheum 41:589–98. https://doi.org/10.1016/j.semarthrit.2011.07.010
Alarcón-Segovia D, Cardiel MH (1989) Comparison between 3 diagnostic criteria for mixed connective tissue disease. Study of 593 patients. J Rheumatol 16:328–334
Mesa A, Somarelli JA, Wu W et al (2013) Differential immunoglobulin class-mediated responses to components of the U1 small nuclear ribonucleoprotein particle in systemic lupus erythematosus and mixed connective tissue disease. Lupus 22:1371–1381. https://doi.org/10.1177/0961203313508444
Hoffman RW, Bezruczko N, Perkins K (2012) An external validation study of a classification of mixed connective tissue disease and systemic lupus erythematosus patients. J Appl Meas 13:205–216
Gordon C, Amissah-Arthur M-B, Gayed M et al (2017) The British Society for Rheumatology guideline for the management of systemic lupus erythematosus in adults. Rheumatology 57:e1–e45. https://doi.org/10.1093/rheumatology/kex286
Bertsias G, Ioannidis JPA, Boletis J et al (2008) EULAR recommendations for the management of systemic lupus erythematosus. Report of a Task Force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics. Ann Rheum Dis 67:195–205. https://doi.org/10.1136/ard.2007.070367
Cozzani E, Drosera M, Gasparini G et al (2014) Serology of lupus erythematosus: correlation between immunopathological features and clinical aspects. Autoimmune Dis 2014:321359. https://doi.org/10.1155/2014/321359
Artim-Esen B, Cene E, ahinkaya Y et al (2014) Cluster analysis of autoantibodies in 852 patients with systemic lupus erythematosus from a single center. J Rheumatol 41:1304–1310. https://doi.org/10.3899/jrheum.130984
Vencovsky J, Williams DG, Field M et al (1992) Clinical associations of IgG antibodies to the ribonucleoprotein p67 polypeptide in patients with systemic lupus erythematosus. Ann Rheum Dis 51:1313–1317
Ter Borg EJ, Groen H, Horst G et al (1990) Clinical associations of antiribonucleoprotein antibodies in patients with systemic lupus erythematosus. Semin Arthritis Rheum 20:164–173
Furtado RNV, Pucinelli MLC, Cristo VV et al (2002) Scleroderma-like nailfold capillaroscopic abnormalities are associated with anti-U1-RNP antibodies and Raynaud’s phenomenon in SLE patients. Lupus 11:35–41
Heimovski FE, Simioni JA, Skare TL (2015) Systemic lupus erythematosus and Raynaud’s phenomenon. An Bras Dermatol 90:837–840. https://doi.org/10.1590/abd1806-4841.20153881
Frodlund M, Dahlström Ö, Kastbom A et al (2013) Associations between antinuclear antibody staining patterns and clinical features of systemic lupus erythematosus: analysis of a regional Swedish register. BMJ Open 3:e003608. https://doi.org/10.1136/bmjopen-2013-003608
Egner W (2000) The use of laboratory tests in the diagnosis of SLE. J Clin Pathol 53:424–432. https://doi.org/10.1136/jcp.53.6.424
Munroe ME, Vista ES, Merrill JT et al (2017) Pathways of impending disease flare in African-American systemic lupus erythematosus patients. J Autoimmun. https://doi.org/10.1016/j.jaut.2016.12.005
Craft J (1992) Antibodies to snRNPs in systemic lupus erythematosus. Rheum Dis Clin North Am 18:311–335
Kelly-Scumpia KM, Nacionales DC, Scumpia PO et al (2007) In vivo adjuvant activity of the RNA component of the Sm/RNP lupus autoantigen. Arthritis Rheum 56:3379–3386. https://doi.org/10.1002/art.22946
Vlachoyiannopoulos PG, Guialis A, Tzioufas G et al (1996) Predominance of IgM anti-U1RNP antibodies in patients with systemic lupus erythematosus. Br J Rheumatol 35:534–541
Migliorini P, Baldini C, Rocchi V et al (2005) Anti-Sm and anti-RNP antibodies. Autoimmunity 38:47–54. https://doi.org/10.1080/08916930400022715
Mahler M, Waka A, Hiepe F et al (2007) Effect of dsDNA binding to SmD-derived peptides on clinical accuracy in the diagnosis of systemic lupus erythematosus. Arthritis Res Ther 9:R68. https://doi.org/10.1186/ar2266
Hochberg MC (1997) Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 40(9):1725. https://doi.org/10.1002/1529-013(199709)40:9<1725::AID-ART29>3.0.CO;2-Y
Petri M, Orbai AM, Alarcon GS et al (2012) Derivation and validation of the systemic lupus international collaborating clinics classification criteria for systemic lupus erythematosus. Arthritis Rheum 64:2677–2686. https://doi.org/10.1002/art.34473
Mahler M, Stinton LM, Fritzler MJ (2005) Improved serological differentiation between systemic lupus erythematosus and mixed connective tissue disease by use of an SmD3 peptide-based immunoassay. Clin Diagn Lab Immunol 12:107–113. https://doi.org/10.1128/CDLI.12.1.107-113.2005
Salmhofer W, Hermann J, Joch M et al (2007) High serum levels of antibodies against the recombinant 70 kDa ribonucleoprotein are useful for diagnosing mixed connective tissue disease. J Eur Acad Dermatol Venereol 21:1047–1053. https://doi.org/10.1111/j.1468-3083.2007.02163.x
Ishizaki J, Saito K, Nawata M et al (2015) Low complements and high titre of anti-Sm antibody as predictors of histopathologically proven silent lupus nephritis without abnormal urinalysis in patients with systemic lupus erythematosus. Rheumatology 54:405–412. https://doi.org/10.1093/rheumatology/keu343
Gunnarsson R, Hetlevik SO, Lilleby V et al (2016) Mixed connective tissue disease. Best Pract Res Clin Rheumatol 30:95–111. https://doi.org/10.1016/j.berh.2016.03.002
Hoffman RW, Sharp GC, Deutscher SL (1995) Analysis of anti-U1 RNA antibodies in patients with connective tissue disease. Association with HLA and clinical manifestations of disease. Arthritis Rheum 38:1837–1844
Gaubitz M, Wegmann C, Schotte H et al (2002) Differentiation of RNP- and SM-antibody subsets in SLE and MCTD patients by a new ELISA using recombinant antigens. Cell Mol Biol (Noisy-le-grand) 48:317–321
Hoffman IEa, Peene I, Meheus L et al (2004) Specific antinuclear antibodies are associated with clinical features in systemic lupus erythematosus. Ann Rheum Dis 63:1155–1158. https://doi.org/10.1136/ard.2003.013417
Kattah NH, Kattah MG, Utz PJ (2010) The U1-snRNP complex: structural properties relating to autoimmune pathogenesis in rheumatic diseases. Immunol Rev 233:126–145. https://doi.org/10.1111/j.0105-2896.2009.00863.x
Bourn R, James JA (2015) Preclinical lupus. Curr Opin Rheumatol 27:433–439. https://doi.org/10.1097/BOR.0000000000000199
Berens-Norman HM, Boackle SA. Editorial (2016) Subduing lupus: can preclinical autoimmune disease be arrested? Arthritis Rheumatol 68:2357–2360. https://doi.org/10.1002/art.39804
Arbuckle MR, McClain MT, Rubertone MV et al (2003) Development of autoantibodies before the clinical onset of systemic lupus erythematosus. N Engl J Med 349:1526–1533. https://doi.org/10.1056/NEJMoa021933
Sharp GC, Irvin WS, LaRoque RL et al (1971) Association of autoantibodies to different nuclear antigens with clinical patterns of rheumatic disease and responsiveness to therapy. J Clin Invest 50:350–359. https://doi.org/10.1172/JCI106502
Sharp GC, Irvin WS, Tan EM et al (1972) Mixed connective tissue disease–an apparently distinct rheumatic disease syndrome associated with a specific antibody to an extractable nuclear antigen (ENA). Am J Med 52:148–159
Yoshida K, Inoue H, Komai K et al (2013) Mixed connective tissue disease is distinct from systemic lupus erythematosus: study of major histocompatibility complex class I polypeptide-related sequence A and HLA gene polymorphisms. Tissue Antigens 81:44–45. https://doi.org/10.1111/tan.12027
Washio M, Fujii T, Kuwana M et al (2014) Lifestyle and other related factors for the development of mixed connective tissue disease among Japanese females in comparison with systemic lupus erythematosus. Mod Rheumatol 24:788–792. https://doi.org/10.3109/14397595.2013.863442
Mesa A, Fernandez M, Wu W et al (2016) Can SLE classification rules be effectively applied to diagnose unclear SLE cases? Lupus 26:150–162. https://doi.org/10.1177/0961203316655212
Carpintero MF, Martinez L, Fernandez I et al (2015) Diagnosis and risk stratification in patients with anti-RNP autoimmunity. Lupus 24:1057–1066. https://doi.org/10.1177/0961203315575586
Guffroy A, Dima A, Nespola B et al (2016) Anti-pseudo-PCNA type 1 (anti-SG2NA) pattern: Track down Cancer, not SLE. Jt Bone Spine 83:330–334. https://doi.org/10.1016/j.jbspin.2015.07.002
Miyamae T, Ito S, Machida H et al (2008) Clinical features and laboratory findings in children with both anti-dsDNA and anti-U1-RNP antibody. Nihon Rinsho Meneki Gakkai Kaishi 31:405–414
Ching KH, Burbelo PD, Tipton C et al (2012) Two major autoantibody clusters in systemic lupus erythematosus. PLoS One 7:e32001. https://doi.org/10.1371/journal.pone.0032001
Jurencák R, Fritzler M, Tyrrell P et al (2009) Autoantibodies in pediatric systemic lupus erythematosus: ethnic grouping, cluster analysis, and clinical correlations. J Rheumatol 36:416–421. https://doi.org/10.3899/jrheum.080588
Alba P, Bento L, Cuadrado MJ et al (2003) Anti-dsDNA, anti-Sm antibodies, and the lupus anticoagulant: significant factors associated with lupus nephritis. Ann Rheum Dis 62:556–560
Bastian H, Roseman J, Mcgwin G et al (2002) Systemic lupus erythematosus in three ethnic groups. XII. Risk factors for lupus nephritis after diagnosis. Lupus 11(3):152–160. https://doi.org/10.1191/0961203302lu158oa
Maverakis E, Patel F, Kronenberg DG et al (2014) International consensus criteria for the diagnosis of Raynaud’s phenomenon. J Autoimmun 48–49:60–65. https://doi.org/10.1016/j.jaut.2014.01.020
Pavlov-Dolijanovic S, Damjanov NS, Vujasinovic Stupar NZ et al (2013) Is there a difference in systemic lupus erythematosus with and without Raynaud’s phenomenon? Rheumatol Int 33:859–865. https://doi.org/10.1007/s00296-012-2449-6
Pavlov-Dolijanovic S, Damjanov NS, Stojanovic RM et al (2012) Scleroderma pattern of nailfold capillary changes as predictive value for the development of a connective tissue disease: a follow-up study of 3,029 patients with primary Raynaud’s phenomenon. Rheumatol Int 32:3039–3045. https://doi.org/10.1007/s00296-011-2109-2
Huang C, Li M, Liu Y et al Baseline characteristics and risk factors of pulmonary arterial hypertension in systemic lupus erythematosus patients. https://doi.org/10.1097/MD.0000000000002761
Hachulla E, Jais X, Cinquetti G et al (2018) Pulmonary arterial hypertension associated with systemic lupus erythematosus. Chest 153(1):143–151. https://doi.org/10.1016/j.chest.2017.08.014
Zhao J, Wang Q, Liu Y et al (2017) Clinical characteristics and survival of pulmonary arterial hypertension associated with three major connective tissue diseases: A cohort study in China. Int J Cardiol 236:432–437. https://doi.org/10.1016/j.ijcard.2017.01.097
Yang X, Mardekian J, Sanders KN et al (2013) Prevalence of pulmonary arterial hypertension in patients with connective tissue diseases: a systematic review of the literature. Clin Rheumatol 32:1519–1531. https://doi.org/10.1007/s10067-013-2307-2
Tselios K, Gladman D, Urowitz M (2016) Systemic lupus erythematosus and pulmonary arterial hypertension: links, risks, and management strategies. Open Access Rheumatol Res Rev 9:1–9. https://doi.org/10.2147/OARRR.S123549
Tellier S, Bader-Meunier B, Quartier P et al (2016) Initial presentation and outcome of pediatric-onset mixed connective tissue disease: A French multicenter retrospective study. Jt Bone Spine 83:369–371. https://doi.org/10.1016/j.jbspin.2015.05.013
Sibilia J, Chatelus E, Meyer A et al (2010) Comment faire le diagnostic et mieux comprendre les myopathies inflammatoires ? L’utilité des auto-anticorps. Presse Med 39:1010–1025. https://doi.org/10.1016/j.lpm.2010.06.008
Sato T, Fujii T, Yokoyama T et al (2010) Anti-U1 RNP antibodies in cerebrospinal fluid are associated with central neuropsychiatric manifestations in systemic lupus erythematosus and mixed connective tissue disease. Arthritis Rheum 62:3730–3740. https://doi.org/10.1002/art.27700
Fujii T (2014) Direct and indirect pathogenic roles of autoantibodies in systemic autoimmune diseases. Allergol Int 63:515–522. https://doi.org/10.2332/allergolint.14-RAI-0801
Katsumata Y, Kawaguchi Y, Baba S et al (2013) Serum antibodies against the 70 k polypeptides of the U1 ribonucleoprotein complex are associated with psychiatric syndromes in systemic lupus erythematosus: a retrospective study. Mod Rheumatol 23:71–80. https://doi.org/10.1007/s10165-012-0624-y
Reichlin M, Broyles TF, Hubscher O et al (1999) Prevalence of autoantibodies to ribosomal P proteins in juvenile-onset systemic lupus erythematosus compared with the adult disease. Arthritis Rheum 42:69–75. https://doi.org/10.1002/1529-0131(199901)42:1<69::AID-ANR9>3.0.CO;2-J
Ho KT, Reveille JD (2003) The clinical relevance of autoantibodies in scleroderma. Arthritis Res Ther 5:80–93
Asano Y, Ihn H, Yamane K et al (2003) The prevalence and clinical significance of anti-U1 RNA antibodies in patients with systemic sclerosis. J Invest Dermatol 120:204–210. https://doi.org/10.1046/j.1523-1747.2003.12028.x
Assassi S, Mayes MD, Arnett FC et al (2010) Systemic sclerosis and lupus: points in an interferon-mediated continuum. Arthritis Rheum 62:589–598. https://doi.org/10.1002/art.27224
Hamaguchi Y, Hasegawa M, Fujimoto M et al (2008) The clinical relevance of serum antinuclear antibodies in Japanese patients with systemic sclerosis. Br J Dermatol 158:487–495. https://doi.org/10.1111/j.1365-2133.2007.08392.x